Helix BioPharma Corp. (HBP.TO) Tuesday said third-quarter loss narrowed to C$2.22 million from C$2.87 million in the comparable quarter last year.
Research and development expenses decreased to C$1.30 million from C$2.14 million last year.
For comments and feedback: editorial@rttnews.com